Skip Navigation


International Immunology Advance Access originally published online on April 11, 2005
International Immunology 2005 17(5):621-635; doi:10.1093/intimm/dxh243
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/5/621    most recent
dxh243v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dieckmann, D.
Right arrow Articles by Schuler, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dieckmann, D.
Right arrow Articles by Schuler, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2005. All rights reserved. For permissions, please e-mail: journals.permissions@oupjournals.org

Optimizing the exogenous antigen loading of monocyte-derived dendritic cells

Detlef Dieckmann1,*, Erwin S. Schultz1,*, Bernhard Ring1, Patrick Chames2, Gerhard Held3, Hennie R. Hoogenboom4 and Gerold Schuler1

1 Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
2 Cellectis SA, Paris, France
3 Department of Medicine, University of the Saarland, Homburg, Germany
4 Merus BV, Utrecht, The Netherlands

Correspondence to: D. Dieckmann; E-mail: detlef.dieckmann{at}derma.imed.uni-erlangen.de

Dendritic cell (DC) vaccination, i.e. the adoptive transfer of antigen-loaded DC, is still at an early stage and requires standardization. In this study, we investigated the exogenous loading of monocyte-derived DCs with HLA class I- and II-restricted peptides, as despite widespread use, little effort has been put into its pre-clinical validation. We found that only mature DCs (m-DC) but not immature DCs (im-DC) could be sufficiently loaded with exogenous class I-restricted peptides and were by far superior in expanding CD8+ primary (Melan-A.A2 peptide-specific) and recall [Influenza matrix peptide (IMP) A2-specific] T cell responses. Primary stimulation with peptide-loaded im-DCs even down-regulated antigen-specific T cell responses. Our results indicate that stimulation with m-DCs is superior in terms of quantity and quality compared with im-DCs, supporting their preferred use in clinical DC trials. Loading of m-DCs with high (10 µM) concentrations generated clearly more Melan-A effectors than loading with 1 or 0.1 µM without any negative effect on the quality (affinity) of the resulting T cells. In contrast to the findings with the Melan-A peptide loading with 10 µM IMP was counter-productive, induced apoptosis and yielded fewer specific T cells of inferior affinity as compared with loading with 1 or 0.1 µM. In sharp contrast to the situation for HLA class I, much higher levels and longer half-lives of peptide–HLA class II complexes were obtainable upon loading of im-DCs with exogenous peptide, but m-DCs were functionally preferable to induce Th1 responses in vitro. Another surprising finding was that, while presentation to T cells upon simultaneous loading of several peptides with highly varying affinities and competing for the same class I or II molecule was possible, in priming experiments peptide competition clearly inhibited T cell induction. Although peptides will obviously vary in their individual properties, our study clearly points to some important principles that should be taken into account.

Keywords: antigen presentation, human, peptide, T cells, vaccination

* These authors contributed equally to this study.

Transmitting editor: R. Steinman


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CVIHome page
X.-L. Huang, Z. Fan, L. Borowski, and C. R. Rinaldo
Multiple T-Cell Responses to Human Immunodeficiency Virus Type 1 Are Enhanced by Dendritic Cells
Clin. Vaccine Immunol., October 1, 2009; 16(10): 1504 - 1516.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Lesimple, E.-M. Neidhard, V. Vignard, C. Lefeuvre, H. Adamski, N. Labarriere, A. Carsin, D. Monnier, B. Collet, G. Clapisson, et al.
Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients
Clin. Cancer Res., December 15, 2006; 12(24): 7380 - 7388.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.